Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Breakout resistance shown as 14.41.
Little resistance above until 15.80.
Stock has been acting like a game of Whack A Mole. Knocked down and then bounces right back up.
Boing X 2
15.oo premarket today.
4.7 Million shares short.
We might go higher.
Boing X 2
25 Million payment on the way.
"Momenta Pharmaceuticals : and Mylan Initiate Phase 1 Clinical Trial for M834, a Proposed Biosimilar of ORENCIA® abatacept
share with twitter share with LinkedIn share with facebook share via e-mail
0
11/10/2016 | 08:03pm CET
By a News Reporter-Staff News Editor at Clinical Trials Week -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA) and Mylan N.V. (NASDAQ, TASE: MYL), announced that dosing has begun in a Phase 1 study to compare the pharmacokinetics, safety and immunogenicity of M834, a proposed biosimilar of ORENCIA (abatacept), to US- and EU-sourced ORENCIA in normal healthy volunteers. Under the Momenta-Mylan collaboration agreement, Momenta has achieved the milestone necessary to earn a $25 million payment from Mylan (see also Pharmaceutical Companies).
http://photos.prnewswire.com/prnvar/20140423/77793
"We are deeply committed to expanding treatment access and providing high-quality and affordable biosimilar options for patients who suffer from autoimmune and inflammatory diseases," said Craig Wheeler, President and Chief Executive Officer of Momenta Pharmaceuticals. "Our collaboration with Mylan, one of the largest generics and specialty pharmaceutical companies in the world, positions us to advance this important biosimilar candidate through the clinic. We believe we have the opportunity to be the leader in offering patients a biosimilar version of ORENCIA."
Mylan President Rajiv Malik commented, "Our pipeline of biosimilar products, which is one of the largest in development in the industry, continues to make exciting advancements and today's milestone for M834 is yet another example of this progress. Our partnership with Momenta is based not only on a shared commitment to bringing more affordable versions of critical biologic products to patients around the world, but also on our mutual passion for science and R&D, and our willingness to invest in it. To date, Mylan has invested more than $1 billion in our biologics and insulin analog programs."
The Phase 1 study is a randomized, double-blind, three-arm, parallel group, single-dose study that is expected to enroll approximately 300 healthy volunteers. The companies plan to report top-line data from this study by the end of 2017.
About M834, a proposed biosimilar of ORENCIA(®) (abatacept)
M834 is developed in collaboration by Mylan N.V. and Momenta Pharmaceuticals. ORENCIA is a fusion protein and the only CTLA-4Ig approved in the US, EU and Japan for the treatment of Rheumatoid Arthritis and the US and EU for the treatment of Juvenile Idiopathic Arthritis. In 2015, worldwide sales of ORENCIA totaled $1.9 billion.
Keywords for this news article include: Antirheumatics, Momenta Pharmaceuticals, Pharmaceutical Companies, Abatacept, Arthritis, Mylan N.V., Joint Diseases, Clinical Research, Drugs and Therapies, Clinical Trials and Studies, Musculoskeletal Diseases and Conditions.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2016, NewsRx LLC
(c) 2016 NewsRx LLC, source Health Newsletters"
Revised Point and Figure pattern.
New target tentative 21.00 from 19.50.
Nice
Boing X 2
Looking strong.
Point and Figure chart new target 19.50.
!3.94 was resistance with little resistance above to 15.28.
Boing X 2
Heavy after hours trading
"16:31 $ 13.65 9,156
16:21 $ 13.65 1,414
16:12 $ 13.6516 High 1,645
16:11 $ 13.505 Low 14,400
16:08 $ 13.5113 6,700
16:00 $ 13.65 286
16:00 $ 13.65 180
16:00 $ 13.65 384
16:00 $ 13.65 35,736
16:00 $ 13.65 2,344
16:00 $ 13.65 255
Read more: http://www.nasdaq.com/symbol/mnta/after-hours#ixzz4PkqJyW4C"
Boing X 2
Popped it right at the end.
YEAH!
Momenta Pharmaceuticals Inc. (MNTA)
Add to watchlist
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
13.65+0.05 (+0.37%)
At close: 4:00 PM EST
Boing X 2
Point and Figure chart has a triple top take out today. New target 18.00
Boing X 2
floblu14,
That was what I was thinking. I was going to post with the numbers .and then didn't
4.8M short as of 10/31 with a 13 plus day to cover.
They are taking it in the knickers.
Boing X 2
New pre grant patent application,
http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=2&f=G&l=50&co1=AND&d=PG01&s1=momenta&OS=momenta&RS=momenta
METHODS OF MANUFACTURING POLYSACCHARIDE COMPOSITIONS
"[0085] In one aspect, described herein are methods of manufacturing a LMWH (e.g., M402) pharmaceutical composition, the method comprising: determining for a sample of the batch whether the activity of the LMWH preparation is within a predetermined range by: exposing the sample to an assay, wherein the assay comprises a population of cells that respond to a stimulant (e.g., a protein, e.g., a cytokine, e.g., SDF1.alpha.) in the absence of the LMWH within a predetermined first range, in response; and determining, in the assay, whether the cellular response in the presence of the LMWH is within a predetermined second range; and formulating the batch of LMWH (e.g., for medical use), to thereby manufacture a LMWH (e.g., M402) pharmaceutical composition. “
Boing X 2
randychub,
Yes I do. The patent applications are listed so any new ones can be reviewed.
I am not seeing other than Momenta showing up in this area.
Sorry that I can't answer the interchangeability question. Dew might. I don't think it is many going for interchangeability at this point. It is a long and hard road to achieve the FDA approval.
Evidenced by the fact that the FDA did their own lab tests to confirm MNTA's Glatopa prior to approval.
You are welcome.
Boing X 2
New patent application continuation,
ANALYSIS OF AMINO ACID COPOLYMER COMPOSITIONS
http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=2&f=G&l=50&co1=AND&d=PG01&s1=momenta&OS=momenta&RS=momenta
"
[0026] Other than molecular weight and amino acid composition, which are specified in the approved label for the product, the label and other available literature for Copaxone.RTM. does not provide detailed information about the physiochemical characteristics of the product. Based on detailed characterization of the product and process kinetics, the inventors have unexpectedly found a signature component of GA, L-pyro-Glutamic Acid (pyro-Glu) GA, that can be evaluated to assess the GA manufacturing process and product quality. In particular, evaluation of pyro-Glu content can identify differences in materials that are not observed by looking at molar mass and amino acid composition alone. By evaluating the pyro-Glu content of a sample of a copolymer, e.g., GA, one can identify non-conforming copolymer compositions. Accordingly, pyro-Glu content can be used to evaluate product and process quality for GA “
It looks like they are locking down the manufacturing with a signature component for Copaxone which Teva does not include in their information.
Boing X 2
floblu14,
Great! Just in time before it is all gone. Let's roll!
Boing X 2
t57,
That is my understanding. We should know in a few hours.
Boing X 2
New pre grant patent application,
"POLYSACCHARIDE COMPOSITIONS AND METHODS OF USE FOR THE TREATMENT AND PREVENTION OF DISORDERS ASSOCIATED WITH PROGENITOR CELL MOBILIZATION “
"[0064] The invention includes methods for treating a subject having, or at risk of having, a metastatic disorder (e.g., a cancer, e.g., a carcinoma or other solid and hematological cancer). In those subjects, treatment may include, but is not limited to, inhibited tumor growth, reduction in tumor mass, reduction in size or number of metastatic lesions, inhibited development of new metastatic lesions, prolonged survival, prolonged progression-free survival, prolonged time to progression, and/or enhanced quality of life. In another embodiment, the subject may have a disorder or condition selected from the group consisting of: an inflammatory disorder, an autoimmune disease, a fibrotic or fibroproliferative disorder or an atopic disorder. Examples of inflammatory disorders include but are not limited to chronic obstructive pulmonary disease, cystic fibrosis, asthma, rheumatoid arthritis, inflammatory bowel disease (including Crohns disease and ulcerative colitis), multiple sclerosis, psoriasis, ischemia-reperfusion injuries, septic shock, age-related macular degeneration (e.g., wet age-related macular degeneration), atherosclerosis, Alzheimer's disease, cardiovascular disease, vasculitis, type I and II diabetes, metabolic syndrome, diabetic retinopathy, restenosis. Examples of autoimmune diseases include but are not limited to asthma, rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, psoriasis, type I diabetes, systemic lupus erythematosus (SLE), Sjogren's syndrome, Hashimoto's thyroiditis, Graves' disease, Guillain-Barre syndrome, autoimmune hepatitis, Myasthenia gravis. Examples of fibrotic diseases include but are not limited to scleroderma, chronic obstructive pulmonary disease, diabetic nephropathy, sarcoidosis, idiopathic pulmonary fibrosis, liver fibrosis, pancreatic fibrosis, cirrhosis, cystic fibrosis, neurofibromatosis, endometriosis, post-operative fibroids, restenosis. Examples of atopic disease include but are not limited to atopic dermatitis, atopic asthma, and allergic rhinitis. The compositions of the invention are administered to a subject having or at risk of developing one or more of the diseases in an effective amount for treating the disorder or condition. “
Boing X 2
New Patent Filing,
http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=4&f=G&l=50&co1=AND&d=PG01&s1=momenta&OS=momenta&RS=momenta
"[0055] In another aspect, the invention features a method of treating an inflammatory or autoimmune or immune disease in a subject by administering to the subject an Fc construct or pharmaceutical composition described herein (e.g., any one of constructs 1-10 and 5*). Exemplary diseases include: rheumatoid arthritis (RA); systemic lupus erythematosus (SLE); ANCA-associated vasculitis; antiphospholipid antibody syndrome; autoimmune hemolytic anemia; chronic inflammatory demyelinating neuropathy; clearance of anti-allo in transplant, anti-self in GVHD, anti-replacement, IgG therapeutics, IgG paraproteins; dermatomyositis; Goodpasture's Syndrome; organ system-targeted type II hypersensitivity syndromes mediated through antibody-dependent cell-mediated cytotoxicity, e.g., Guillain Barre syndrome, CIDP, dermatomyositis, Felty's syndrome, antibody-mediated rejection, autoimmune thyroid disease, ulcerative colitis, autoimmune liver disease; idiopathic thrombocytopenia purpura; Myasthenia Gravis, neuromyelitis optica; pemphigus and other autoimmune blistering disorders; Sjogren's Syndrome; autoimmune cytopenias and other disorders mediated through antibody-dependent phagocytosis; other FcR-dependent inflammatory syndromes, e.g., synovitis, dermatomyositis, systemic vasculitis, glomerulitis and vasculitis. "
Boing X 2
Not Long Now,
"USPTO IPR re Teva’s 40mg patents on 5/12/16 (decision Aug 2016) “,
" patent trial may be unnecessary if the USPTO IPR scheduled for 5/2/16 results in the USPTO invalidating Teva’s 40mg patents.”
Things could start looking up going forward.
Boing X 2
Regulardoc,
"Sanjay Valvani, a portfolio manager at Visium Asset Management who was charged last week with insider trading, was found dead on Monday, apparently the victim of a suicide, a New York police official said."
Boing X 2
Regulardoc,
Here you go.
VISIUM ASSET MANAGEMENT, LP 03/31/2016 0 (16,995) Sold Out
Read more: http://www.nasdaq.com/symbol/mnta/institutional-holdings?page=3#ixzz4C64fxKYd
Boing x 2
floblu14,
I voted no on #4.
Excessive at this point in time.
Boing X 2.
Pre grant patent applications filed.
PHARMACEUTICAL COMPOSITIONS
http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=3&f=G&l=50&co1=AND&d=PG01&s1=momenta&OS=momenta&RS=momenta
This disclosure relates to therapeutic and/or diagnostic formulations with altered, optimized, and/or improved characteristics.
061] In certain embodiments, the glycol split LMWH preparation is an M402 preparation. In one embodiment, the M402 preparation has a molecular weight distribution such that 10-40% of the oligosaccharides of the preparation have a molecular weight <3000 Da; 45-65% of the oligosaccharides have a molecular weight between 3000-8000 Da, and 15-30% of the oligosaccharides have a molecular weight >8000 Da.
Another filing,
Pharmaceutical Compositions Comprising Pyrophosphate
http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=2&f=G&l=50&co1=AND&d=PG01&s1=momenta&OS=momenta&RS=momenta
1. An aqueous pharmaceutical composition, the composition comprising a. a therapeutic agent, e.g., a therapeutic polypeptide or a therapeutic polysaccharide; and b. pyrophosphate, e.g., 5 mM-250 mM pyrophosphate.
0009] In some embodiments, the therapeutic agent is a therapeutic antibody preparation (e.g., abciximab, adalimumab, alemtuzumab, basiliximab, bevacizumab, certolizumab, cetuximab, daclizumab, eculizumab, efalizumab, gemtuzumab, ibritumomab, infliximab, muromonab-CD3, natalizumab, omalizumab, palivizumab, panitumumab, ranibizumab, rituximab, tositumomab, or trastuzumab).
Boing X 2
Sure,
Don't twist my words.
And while we are at it we can just give them the 430M bond.!
Boing X 2
Are you kidding on selling it for a dollar?
Our damages continue to amount on our lawsuit. If we prevail the damage claim is getting bigger by the minutes.
Boing X 2
New pre grant patent application
POLYSACCHARIDE COMPOSITIONS AND RELATED METHODS
M402
http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PG01&s1=momenta&OS=momenta&RS=momenta
As this is based off of heparin, I hope they are covering the water front to prevent stealing our patent and future patents.
Boing X 2
DewDiligence,
I agree.
I was being very careful on any FDA discussions. I alluded to the fact the FDA might be coming around to our way of thinking as they already have the molecules tied down upon any submission. It would reduce development costs to not have to wait years.
Boing X 2
Some tidbits on the DB CC call this am.
Craig said continuing to show good results on phase 11 Necuparanib.
Said the investment community should start to think of us as an autoimmune company. Smart move in my opinion.
Starting clinical trial in two weeks on our autoimmune drug.
Looking at outside the US sales of Glatopa.
Thinks the 6 months heads up on exclusivity will eventually go away. That will help.
Thinks the current FDA is becoming more receptive to our position on how the approval process should evolve to keep costs down. My words on what he said.
Said they are getting ready for the launch of 3 times a week Glatopa. 1st quarter.
It was again mentioned over 3 years of cash. Also a new drug each year by 2019
As always listen to the CC yourself. Sort of garbled on the sound this am.
Boing X 2
DewDiligence,
Thank you. Right you are it is an increase to 35%.
I think the IPR hearing will have an impact on what happens on our future Glatopa sales. Do we get to start selling three times a week shots in the first quarter of next year or not.
Not arguing, just giving my thoughts.
The CC sounded positive to me.
Big One. No need to raise cash. Enough cash for 3 years and it sounds like they expect we will be selling 40mg Glatopa prior to that along with increasing sales of the 20mg.
Will be getting another 60M prior to end of year on sharing agreements.
Glatopa sales up 5% over last quarter.
They feel strong about our 40mg Glatopa patents. It sounds like they feel we will be selling in the first quarter 2017. My interpretation.
Should have a ruling on Glatopa by August prior to Sept. trial.
They are excited about necuparanib.
IVig trials coming up. My words here - I am guessing we will be in a whole new separate class ahead of the field on these drugs and trials.
No mention on the heparin litigation. No profit this quarter, due to pricing pressure, will just add to our damages if we prevail.
Nothing downbeat to me in this CC.
My thoughts on what I heard.
Boing X 2
Sorry to the board as I saw May 2nd. Must have missed seeing the 1 when I looked.
Boing X 2
correction,
Starts today.
Boing X 2
Hearing on Teva patents starts tomorrow
Tomorrow, tomorrow I love ya tomorrow
You're only a day away
Boing X 2
Likely ust a matter of time for fast track approval. IMHO!
http://www.curetoday.com/publications/cure/2016/gastrointestinal-2016/searching-on-all-fronts-changing-the-outlook-for-those-with-pancreatic-cancer
Boing X 2
Pre grant patent application,
SIALYLATED GLYCOPROTEINS
"
[0101] In some embodiments, methods described herein are useful for controlling the sialylation of a reference polypeptide (e.g., a reference glycoprotein). In some embodiments, polypeptide (e.g., glycoprotein) preparations described herein have predetermined or target levels of glycans (e.g., branched glycans having a sialic acid on an .alpha.1,3 arm, and/or branched glycans having a sialic acid on an .alpha.1,6 arm, and/or branched glycans having a sialic acid on an .alpha.1,3 arm and on an .alpha.1,6 arm), where the predetermined levels are substantially similar to or different from (e.g., higher or lower than) levels of glycans (e.g., branched glycans having a sialic acid on an .alpha.1,3 arm, and/or branched glycans having a sialic acid on an .alpha.1,6 arm, and/or branched glycans having a sialic acid on an .alpha.1,3 arm and on an .alpha.1,6 arm) in a reference polypeptide product (e.g., glycoprotein product). Nonlimiting, exemplary reference glycoprotein products can include abatacept (Orencia.RTM., Bristol-Myers Squibb), abciximab (ReoPro.RTM., Roche), adalimumab (Humira.RTM., Bristol-Myers Squibb), aflibercept (Eylea.RTM., Regeneron Pharmaceuticals), alefacept (Amevive.RTM., Astellas Pharma), alemtuzumab (Campath.RTM., Genzyme/Bayer), basiliximab (Simulect.RTM., Novartis), belatacept (Nulojix.RTM., Bristol-Myers Squibb), belimumab (Benlysta.RTM., GlaxoSmithKline), bevacizumab (Avastin.RTM., Roche), canakinumab (Ilaris.RTM., Novartis), brentuximab vedotin (Adcetris.RTM., Seattle Genetics), certolizumab (CIMZIA.RTM., UCB, Brussels, Belgium), cetuximab (Erbitux.RTM., Merck-Serono), daclizumab (Zenapax.RTM., Hoffmann-La Roche), denileukin diftitox (Ontak.RTM., Eisai), denosumab (Prolia.RTM., Amgen; Xgeva.RTM., Amgen), eculizumab (Soliris.RTM., Alexion Pharmaceuticals), efalizumab (Raptiva.RTM., Genentech), etanercept (Enbrel.RTM., Amgen-Pfizer), gemtuzumab (Mylotarg.RTM., Pfizer), golimumab (Simponi.RTM., Janssen), ibritumomab (Zevalin.RTM., Spectrum Pharmaceuticals), infliximab (Remicade.RTM., Centocor), ipilimumab (Yervoy.TM., Bristol-Myers Squibb), muromonab (Orthoclone OKT3.RTM., Janssen-Cilag), natalizumab (Tysabri.RTM., Biogen Idea, Elan), ofatumumab (Arzerra.RTM., GlaxoSmithKline), omalizumab (Xolair.RTM., Novartis), palivizumab (Synagis.RTM., Medlmmune), panitumumab (Vectibix.RTM., Amgen), ranibizumab (Lucentis.RTM., Genentech), rilonacept (Arcalyst.RTM., Regeneron Pharmaceuticals), rituximab (MabThera.RTM., Roche), tocilizumab (Actemra.RTM., Genentech; RoActemra, Hoffman-La Roche) tositumomab (Bexxar.RTM., GlaxoSmithKline), and trastuzumab (Herceptin.RTM., Roche). “
Boing X 2
I do believe we already have an agreement with them if I remember right.
https://www.statnews.com/2016/04/14/chinese-biopharma-kendall/?s_campaign=stat:rss
Boing X 2
Patent application pre grant approval
DEFINED GLYCOPROTEIN PRODUCTS AND RELATED METHODS
http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=2&f=G&l=50&co1=AND&d=PG01&s1=momenta&OS=momenta&RS=momenta
Boing X 2
DewDilligence,
Thank you.
Boing X 2
Would anyone like to comment about this information that I just found? Has anyone on the board heard anything?
"Enforcement » Premerger Notification Program » Early Termination Notices » 20160629: Mylan N.V.; Momenta Pharmaceuticals, Inc.
20160629: Mylan N.V.; Momenta Pharmaceuticals, Inc.
DATE: February 9, 2016
TRANSACTION NUMBER: 20160629
ACQUIRING PARTY: Mylan N.V.
ACQUIRED PARTY: Momenta Pharmaceuticals, Inc.
GRANTING STATUS: Granted
ACQUIRED ENTITIES
Momenta Pharmaceuticals, Inc.”
https://www.ftc.gov/enforcement/premerger-notification-program/early-termination-notices/20160629
Boing X 2
biopearl,
Thank you! You are most welcome. It did get my attention on what all they are going after.
Boing X 2
New pre grant patent application.
METHODS FOR THE TREATMENT OF NEURODEGENERATION
http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=2&f=G&l=50&co1=AND&d=PG01&s1=momenta&OS=momenta&RS=momenta
"
32. The method of claim 4, wherein said neurodegeneration is related to a disease selected from the group consisting of age-related dementia, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), cerebellar ataxia, Creutzfedt-Jakob disease, Down's syndrome, frontotemporal lobar degenerations/dementia, Huntington's disease, inclusion body myositis, Lewy body dementia, chronic inflammatory demyelinating polyneuropathy, Guillain-Barre syndrome, Charcot-Marie-Tooth syndrome, myasthenia gravis, Lambert-Eaton myasthenic syndrome, multifocal motor neuropathies, multiple sclerosis, multiple-system atrophy, Parkinson's disease, vascular dementia, Lennox-Gastaut syndrome, ataxia telangiectasia, neurodegenerative Lyme disease, acute disseminating encephalomyelitis, acute idiopathic dysautonomia, adrenoleukodystrophy, demylelinative brain stem encephalitis, demyelinating neuropathy associated with monoclonal IgM, HTLV-1-associated myelopathy, other paraneoplastic neurodegeneration, neuropathy or encephalopathies, lumbosacral or brachial plexitis, POEMS syndrome, post-infection cerebellar ataxia, presbycusis, spinocerebellar ataxia, other peripheral neuropathies (e.g., mononeuropathy, mononeuritis multiplex, polyneuropathy, autonomic neuropathy, and neuritis), and vascular dementia.
33. The method of claim 14, wherein said neurodegeneration is related to a disease selected from the group consisting of age-related dementia, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), cerebellar ataxia, Creutzfedt-Jakob disease, Down's syndrome, frontotemporal lobar degenerations/dementia, Huntington's disease, inclusion body myositis, Lewy body dementia, chronic inflammatory demyelinating polyneuropathy, Guillain-Barre syndrome, Charcot-Marie-Tooth syndrome, myasthenia gravis, Lambert-Eaton myasthenic syndrome, multifocal motor neuropathies, multiple sclerosis, multiple-system atrophy, Parkinson's disease, vascular dementia, Lennox-Gastaut syndrome, ataxia telangiectasia, neurodegenerative Lyme disease, acute disseminating encephalomyelitis, acute idiopathic dysautonomia, adrenoleukodystrophy, demylelinative brain stem encephalitis, demyelinating neuropathy associated with monoclonal IgM, HTLV-1-associated myelopathy, other paraneoplastic neurodegeneration, neuropathy or encephalopathies, lumbosacral or brachial plexitis, POEMS syndrome, post-infection cerebellar ataxia, presbycusis, spinocerebellar ataxia, other peripheral neuropathies (e.g., mononeuropathy, mononeuritis multiplex, polyneuropathy, autonomic neuropathy, and neuritis), and vascular dementia.
34. The method of claim 15, wherein said neurodegeneration is related to a disease selected from the group consisting of age-related dementia, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), cerebellar ataxia, Creutzfedt-Jakob disease, Down's syndrome, frontotemporal lobar degenerations/dementia, Huntington's disease, inclusion body myositis, Lewy body dementia, chronic inflammatory demyelinating polyneuropathy, Guillain-Barre syndrome, Charcot-Marie-Tooth syndrome, myasthenia gravis, Lambert-Eaton myasthenic syndrome, multifocal motor neuropathies, multiple sclerosis, multiple-system atrophy, Parkinson's disease, vascular dementia, Lennox-Gastaut syndrome, ataxia telangiectasia, neurodegenerative Lyme disease, acute disseminating encephalomyelitis, acute idiopathic dysautonomia, adrenoleukodystrophy, demylelinative brain stem encephalitis, demyelinating neuropathy associated with monoclonal IgM, HTLV-1-associated myelopathy, other paraneoplastic neurodegeneration, neuropathy or encephalopathies, lumbosacral or brachial plexitis, POEMS syndrome, post-infection cerebellar ataxia, presbycusis, spinocerebellar ataxia, other peripheral neuropathies (e.g., mononeuropathy, mononeuritis multiplex, polyneuropathy, autonomic neuropathy, and neuritis), and vascular dementia.
35. The method of claim 19, wherein said neurodegeneration is related to a disease selected from the group consisting of age-related dementia, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), cerebellar ataxia, Creutzfedt-Jakob disease, Down's syndrome, frontotemporal lobar degenerations/dementia, Huntington's disease, inclusion body myositis, Lewy body dementia, chronic inflammatory demyelinating polyneuropathy, Guillain-Barre syndrome, Charcot-Marie-Tooth syndrome, myasthenia gravis, Lambert-Eaton myasthenic syndrome, multifocal motor neuropathies, multiple sclerosis, multiple-system atrophy, Parkinson's disease, vascular dementia, Lennox-Gastaut syndrome, ataxia telangiectasia, neurodegenerative Lyme disease, acute disseminating encephalomyelitis, acute idiopathic dysautonomia, adrenoleukodystrophy, demylelinative brain stem encephalitis, demyelinating neuropathy associated with monoclonal IgM, HTLV-1-associated myelopathy, other paraneoplastic neurodegeneration, neuropathy or encephalopathies, lumbosacral or brachial plexitis, POEMS syndrome, post-infection cerebellar ataxia, presbycusis, spinocerebellar ataxia, other peripheral neuropathies (e.g., mononeuropathy, mononeuritis multiplex, polyneuropathy, autonomic neuropathy, and neuritis), and vascular dementia.”
Boing X 2